Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses
详细信息 查看全文
- 作者：Bernard C么t茅 ; Jason D. Burch ; Ernest Asante-Appiah ; Chris Bayly ; Leanne B茅dard ; Marc Blouin ; Louis-Charles Campeau ; Elizabeth Cauchon ; Manuel Chan ; Am ; ine Chefson ; Nathalie Coulombe ; W ; a Cromlish ; Smita Debnath ; Denis Desch锚nes ; Kristina Dupont-Gaudet ; Jean-Pierre Falgueyret ; Robert Forget ; S茅bastien Gagn茅 ; Danny Gauvreau ; Melina Girardin ; S茅bastien Guiral ; et al.
- 关键词：Non-nucleoside reverse transcriptase ; HIV ; Triazolinone ; Pyridone ; Inhibitor
- 刊名：Bioorganic and Medicinal Chemistry Letters
- 出版年：1 February, 2014
- 年：2014
- 卷：24
- 期：3
- 页码：917-922
- 全文大小：2365 K
文摘
The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of pyridone 36. In cell cultures, this new NNRTI shows a superior potency profile against a range of wild type and clinically relevant, resistant mutant HIV viruses. The overall favorable preclinical pharmacokinetic profile of 36 led to the prediction of a once daily low dose regimen in human. NNRTI 36, now known as MK-1439, is currently in clinical development for the treatment of HIV infection.